LifeVantage Corporation (LFVN) compared with its closest peers (RLYB, GANX, ACET, MAIA, DWTX): P/E 11.6 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Rallybio Corporation (RLYB) | $89.22M | -0.4 |
| Gain Therapeutics, Inc. (GANX) | $87.29M | -5.3 |
| Adicet Bio, Inc. (ACET) | $85.86M | -0.5 |
| MAIA Biotechnology, Inc. (MAIA) | $84.55M | -2.2 |
| Dogwood Therapeutics, Inc. (DWTX) | $83.62M | -0.6 |
| Verrica Pharmaceuticals Inc. (VRCA) | $83.15M | -5.0 |
| Cingulate Inc. (CING) | $80.49M | -1.0 |
| Elicio Therapeutics, Inc. (ELTX) | $79.63M | -3.1 |
| Lunai Bioworks Inc. (LNAI) | $78.35M | — |
| Annovis Bio, Inc. (ANVS) | $77.12M | -2.5 |
| Stock P/E | 11.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -46.6% |
| vs Industry | -31.8% |
LFVN overview · LFVN earnings · LFVN financials · LFVN KPIs · LFVN investor relations · LFVN ownership · LFVN filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.